News | September 17, 2025
ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
